BIO-TECHNE TO PRESENT AT THE J.P. MORGAN HEALTHCARE CONFERENCE

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 4:30 p.m. EST. Chuck Kummeth, CEO, will lead the presentation, which will be available via a live webcast on the company’s Investor Relations page. Bio-Techne specializes in high-quality purified proteins, reagent solutions, and diagnostic products, generating approximately $931 million in net sales in fiscal 2021. The company employs around 2,700 people globally.

MINNEAPOLIS, Jan. 3, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 40^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 4:30 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne's genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx^® Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $931 million in net sales in fiscal 2021 and has approximately 2,700 employees worldwide.

Contact:  David Clair, Senior Director, Investor Relations & Corporate Development
               david.clair@bio-techne.com
               612-656-4416

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-jp-morgan-healthcare-conference-301451016.html

SOURCE Bio-Techne Corporation

FAQ

When will Bio-Techne present at the J.P. Morgan Healthcare Conference?

Bio-Techne will present at the J.P. Morgan Healthcare Conference on January 12, 2022, at 4:30 p.m. EST.

Who is presenting for Bio-Techne at the conference?

Chuck Kummeth, the President and CEO of Bio-Techne, will present at the conference.

How can I watch the Bio-Techne presentation?

The presentation can be accessed via a live webcast on Bio-Techne's Investor Relations website.

What is the net sales figure for Bio-Techne in fiscal 2021?

Bio-Techne generated approximately $931 million in net sales in fiscal 2021.

What products does Bio-Techne offer?

Bio-Techne develops purified proteins, reagent solutions, diagnostic products, and genomic tools.